Drugs / BMX-001
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06620029 | Apr 2025 → Mar 2027 expected | endometrial cancer, ovarian cancer | BioMimetix JV, LLC | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT02655601 | Sep 2018 → Aug 2023 | anaplastic astrocytoma, glioblastoma | BioMimetix JV, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03386500 | Nov 2017 → Oct 2026 expected | anal squamous cell carcinoma | University of Nebraska | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02990468 | Apr 2017 → Feb 2020 | head and neck cancer | BioMimetix JV, LLC | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06532279 | Jun 2025 → Jan 2027 expected | carcinoma in situ of hypopharynx, carcinoma in situ of nasopharynx, carcinoma in situ of oropharynx, hypopharynx squamous cell carcinoma +6 | NRG Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT05254327 | Aug 2022 → May 2027 expected | rectal cancer | University of Nebraska | Recruiting | No outcome recorded |
| Phase 2 | NCT04607642 | Jul 2021 → Jul 2023 | head and neck cancer | BioMimetix JV, LLC | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03608020 Comparator | Oct 2018 → Dec 2023 | metastatic malignant neoplasm in the brain | BioMimetix JV, LLC | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMX-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02990468 ↗ |
| Known as | MnTnBuOE-2-PyP5+ | “Nonclinical Safety and Toxicokinetics of MnTnBuOE-2-PyP5+ (BMX-001).” PMID 27098749 ↗ Apr 2016 |
| Modality | Small molecule | “A recently developed compound, BMX-001 (MnTnBuOE-2- PyP5+), is among the most highly potent metalloporphyrin compounds which reduce oxidative stress, thereby protecting normal...” NCT03386500 ↗ |
| Route | Subcutaneous | “BMX-001 will be given by subcutaneous injection with a loading dose of 28 mg/subject given within 4 days prior to initiation of radiation therapy and followed by biweekly...” NCT02655601 ↗ |